IVAX Names Weiner Senior Vice President For IVAX Research

     
BW20030331000100  20030331T145428Z UTC


( BW)(IVAX-CORPORATION)(IVX) IVAX Names Weiner Senior Vice President 
For IVAX Research

    Business Editors
    UK REGULATORY NEWS

    MIAMI--(BUSINESS WIRE)--March 31, 2003--

IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that Dr. Dan
Weiner has been appointed senior vice president, global clinical
development - IVAX Research, Inc. Prior to this appointment Dr. Weiner
was working with IVAX in a consulting capacity. Dr. Weiner will report
to Dr. Phillip Frost, chairman and CEO of IVAX, and will be
responsible for regulatory affairs, biometrics, new drug development
and clinical development.

Dr. Weiner graduated from the University of Kentucky with a doctoral
degree in Mathematical Statistics, with emphasis on compartmental
modeling. Since that time he has held several management positions
including Head, Biostatistics, Merrell Dow Pharmaceuticals; Vice
President, Statistical Consultants, Inc.; Vice President, Syntex
Development Research; and Sr. Vice President and Principal Scientist,
Quintiles. Prior to joining IVAX, he most recently served as Senior
Vice President, Technology Deployment, for Pharsight Corporation.

Dr. Weiner has extensive drug development experience and has served as
an expert consultant to the FDA on pharmacokinetic modeling and
bioequivalence assessment. He has also served as a drug development
consultant to a number of pharmaceutical companies. He is the
co-author of Pharmacokinetic and Pharmacodynamic Data Analysis:
Concepts and Applications. Dr. Weiner is a past Adjunct Associate
Professor with the Colleges of Pharmacy and Environmental Health at
the University of Cincinnati; a past President of the Greater
Cincinnati Chapter of the American Statistical Association; a past
Vice-Chair of the Biostatistics Subsection of PMA; and a past member
of the Editorial Advisory Board for the Journal of Pharmaceutical
Sciences.

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.

Copies of this and other news releases may be obtained free of charge
from IVAX' website at http://www.ivax.com.

   Short Name: IVAX Corporation
   Category Code: MSC
   Sequence Number: 00003475
   Time of Receipt (offset from UTC): 20030331T143519+0100

    --30--tav/ny

    CONTACT: IVAX Corporation, Miami
             Jim Whitlow, 305/575-6043

    KEYWORD: UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL 
    SOURCE: IVAX Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com